Bismuth lipophilic nanoparticles (BisBAL NP) inhibit the growth of tumor cells in a mouse melanoma model

Claudia María García-Cuellar, Claudio Cabral-Romero, Rene Hernández-Delgadillo, Juan Manuel Solis-Soto, Irene Meester, Yesennia Sánchez-Pérez, Sergio Eduardo Nakagoshi-Cepeda, Nayely Pineda-Aguilar, Rosa Isela Sánchez-Nájera, María Argelia Akemi Nakagoshi-Cepeda, Shankararaman Chellam

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Aim: The objective of this study was to analyze the antitumor effect of BisBAL NP in a mouse melanoma model. Materials and Methods: The antitumor activity of BisBAL NP on murine B16-F10 melanoma cells was determined both in vitro (PrestoBlue cell viability assay and Live/Dead fluorescence) and in vivo, in a mouse model, with the following 15-day treatments: BisBAL NP, negative control (PBS), and cell-death control (docetaxel; DTX). Mouse survival and weight, as well as the tumor volume, were recorded daily during the in vivo study. Results: BisBAL NP were homogeneous in size (mean diameter, 14.7 nm) and bismuth content. In vitro, 0.1 mg/mL BisBAL NP inhibited B16-F10 cell growth stronger (88%) than 0.1 mg/mL DTX (82%) (*p<0.0001). In vivo, tumors in mice treated with BisBAL NP (50 mg/kg/day) or DTX (10 mg/kg/day) were 76% and 85% smaller than the tumors of negative control mice (*p<0.0001). The average weightof mice was 18.1 g and no statistically significant difference was detected among groups during the study. Alopecia was only observed in all DTX-treated mice. The survival rate was 100% for the control and BisBAL NP groups, but one DTX-treated mouse died at the end of the treatment period. The histopathological analysis revealed that exposure to BisBAL NP was cytotoxic for tumor tissue only, without affecting the liver or kidney. Conclusion: BisBAL NP decreased the tumor growing in a mouse melanoma model without secondary effects, constituting an innovative low-cost alternative to treat melanoma.

Original languageEnglish
Pages (from-to)2548-2557
Number of pages10
JournalAnti-Cancer Agents in Medicinal Chemistry
Issue number14
Early online date15 Feb 2022
Publication statusPublished - 2022

Bibliographical note

Funding Information:
This research study has been supported by CONACyT, grant A1-S-20148.

Funding Information:
The authors want to thank CONACyT for the grant A1-S-20148; an approved project by the Sectorial Fund for Education Research. The authors thank Ricardo Gaxiola-Centeno from CINVESTAV-Mexico for mice maintenance, and Horacio Alejandro Ovalle-Estrada from the University of Monterrey (UDEM) for technical support.

Publisher Copyright:
© 2022 Bentham Science Publishers.


Dive into the research topics of 'Bismuth lipophilic nanoparticles (BisBAL NP) inhibit the growth of tumor cells in a mouse melanoma model'. Together they form a unique fingerprint.

Cite this